Samsung Biologics Q2 Operating Profit Exceeds 1 Trillion Won, Record Earnings and Stock Outlook?

Samsung Biologics has achieved its highest-ever performance, surpassing 1 trillion won in cumulative operating profit for the first half of 2026. Driven by the full operation of its Plants 1-4 and a strong dollar, large-scale buying from foreign investors is pouring in.

Overwhelming Q2 Earnings: 3 Key Drivers of Growth

Samsung Biologics recorded 1.32 trillion won in sales and 586.4 billion won in operating profit in Q2 2026, showing rapid growth of 30% and 23%, respectively, compared to the same period last year. Three major factors contributed to this record-breaking performance.

• Maximized Manufacturing Competitiveness: Plants 1-4 in Songdo, Incheon, entered full operational efficiency, maximizing production output.
• Exchange Rate Benefits: As most contracts with global pharmaceutical companies are settled in dollars, the recent strong dollar trend acted as a powerful premium for won-converted earnings.
• Robust Profit Defense: Despite the initial costs reflected ahead of the operation of Plant 5 and the Rockville facility in the US, the company proved its solid fundamentals by maintaining an overwhelming operating profit margin in the 40% range.

Foreign Buying Concentration: Where is the Stock Heading in the Second Half?

Immediately after the earnings announcement, strong foreign buying flowed into Samsung Biologics, even amidst a panic-selling market where the KOSPI plunged by over 5% due to a correction in US large-cap tech stocks. The securities industry predicts that achieving the upper end of the annual sales growth guidance (20%) will be smooth, given the scheduled early operation of Plant 5 and additional CMO contracts with global big pharma. Highlighted as a reliable defensive stock, expectations for an upward revision of target prices are spreading across stock discussion boards and communities.

Related FAQ

Q. Did the labor union strike affect the earnings?

A. Although there was a short-term production disruption of about 150 billion won due to the strike in Q2, the impact on overall earnings was minimized through process optimization and utilization of existing inventory. The company recorded stellar earnings that more than offset the disruption.

Q. What is the most important investment momentum to watch in the second half?

A. The ramp-up speed of the new Plant 5 and securing additional CMO orders for new blockbuster drugs, such as Alzheimer's treatments, are the most crucial points that will drive earnings and stock prices in the second half of the year.